维普中文期刊产品整合服务
12篇 您的检索式:作者名="Kersten MJ"
    题名 作者 年代 出处 被引量
1Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer?显示文摘AIM: To investigate the effect of the establishment of in-house multidisciplinary team (MDT) availability (iMDTa) on survival in upper gastrointestinal cancer (UGI) patients. METHODS: In 2001, a cancer centre with irradiation and chemotherapy facilities was established in the Norwegian county of West Agder with a change of iMDTa (WA/MDT-Change). 'iMDTa'-status was defined according to the availability of the necessary specialists within one institution on one campus, serving the population of one county. We compared survival rates during 2000-2008 for UGI patients living in counties with (MDT-Yes), without (MDT-No), with a mix (MDT-Mix) and WA/MDT-Change. Survival was calculated with Kaplan-Meier method. Cox model was used to uncover differences between counties with different MDT status when adjusted for age, sex and stage. RESULTS: We analyzed 395 patients from WA/MDT-Change and compared their survival to 12 135 UGIpatients from four other Norwegian regions. Median overall survival for UGI patients in WA/MDT-Change increased from 129 to 300 d from 2000-2008, P = 0.001. The regions with the highest level of iMDTa achieved the largest decrease in risk of death for UGI cancers (compared to the county with MDT-Mix: MDT-Yes 11%, P <0.05 and WA/MDT-Change 15%, P < 0.05). Analyzing the different tumour entities separately, patients living in the WA/MDT-Change county reached a statisti-cally significant reduction in the risk of death [hazard ratios (HR)] compared to patients in the county with MDT-Mix for oesophageal and gastric, but not for pan-creatic cancer. HR for the study period 2000-2004 are given first and then for the period 2005-2008: The HR for oesophageal cancers was reduced from [HR = 1.12; 95%CI: 0.75-1.68 to HR = 0.60, 95%CI: 0.38-0.95] and for gastric cancers from [HR = 0.87, 95%CI: 0.66-1.15 to HR = 0.63, 95%CI: 0.43-0.93], but not for pancreatic cancer [HR = 1.04-, 95%CI: 0.83-1.3 for 2000-2004 and HR = 1.01, 95%CI: 0.78-1.3 for 2005-2008]. UGI patients treated during the second study period in the county of WA/MDT-Change had a higher probability of receiving chemotherapy. In the first study period, only one out of 43 patients (2.4%, 95%CI: 0-6.9) received chemotherapy, compared to 18 of 42 patients diagnosed during 2005-2008 (42.9%, 95%CI: 28.0-57.8). CONCLUSION: Introduction of iMDTa led to a two-fold increase of UGI patients, whereas no increase in survival was found in the MDT-No or MDT-Mix counties.Christian Kersten Milada Cvancarova Svein Mjland Odd Mjland 2013World Journal of Gastrointestinal Oncology2013,5,3:3
2Angiopoietin-like 4 protein elevates the prosurvival intracellular O2 -:H2O2 ratio and confers anoikis resistance to tumors显示文摘Zhu P Tan MJ Huang RL Tan CK Chong HC Pal M Lam CR Boukamp P Pan JY Tan SH Kersten S Li HY Ding JL Tan NS 0,,03:1
3Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy : a system- atic review and meta- analysis显示文摘Persoon S Kersten MJ 2013Cancer Treatment Reviews2013,39,6:1
4Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TriM显示文摘Kneppers E van der Holt B Kersten MJ 2011Blood2011,118,:1
5Agarcyto:A Novel cell-processing method for multiplex molecular diagonistic analyses of the uterine cervix 显示文摘Harold MJ Kerstens Johama CM 2000J Histol cyto2000,48,5:1
6Temozolomide followed by combined immumotherapy with GM-CSF,low-dose IL2 and IFN alpha in patients with metastatic melanoma显示文摘de Gast GC Batchelor D Kersten MJ 2003Br J Cancer2003,88,2:1
7Temozolomide followed by combined immumotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma 显示文摘 Batchelor D Kersten MJ 2003Br J Cancer2003,88,2:1
8Lenalidomide maintenance after nonmyeloablative al ogeneic stem celltransplantation in multiple myeloma is not feasible:results of the HOVON 76 Trial显示文摘Kneppers E van der Holt B Kersten MJ 2011{H}Blood2011,,09:1
9Interim analysis of dose-escalation stage of a phase 1b study evaluating safety and pharmacology of GS-9820,a second generation selective PI3Kd inhibitor in recurrent lymphoid malignancies显示文摘Kater AP Tonino SH Kersten MJ 2013Blood(ASH Annual Meeting Abstracts)2013,122,:1
10Treatment of AIDS-related non-Hodgkin' s lymphoma with chemotherapy (CMOP) and r-hu-G-CSF:clinical outcome and effect on HIV-1 viral load显示文摘Kersten MJ Verduyn TJ Reissp P 1998Ann Oncol1998,9,10:1
11Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment显示文摘Glas AM Kersten MJ Delahaye LJ 2005Blood2005,105,1:1
12Long-term treatment of transfusional iron overload with the oral iron chelator,1,2-dimethy1-3-hydroxypyrid-4one (deferiprone)显示文摘MJ Kersten R Lange MEP Smeets 1995Abstracts/Netherlands Journal of Medicine1995,47,5:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费